Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement, Press Release PICI Appoints John Connolly as Chief Scientific Officer Research Project CANDEL: A first-of-its-kind data analysis engine for scientific discovery Cancer Research Heroes, Partner Highlight A Science-Driven Partnership Announcement Our Stance on Equality Cancer Research Heroes The Power of Patient Samples Research Project REVIVE: Can we outsmart cancer by learning from the past?